Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
about
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?From bench to bedside: immunotherapy for prostate cancerCell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cellsCullin-1 promotes cell proliferation via cell cycle regulation and is a novel in prostate cancer.Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats.Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.Effects of oxygen on the antigenic landscape of prostate cancer cells.Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.Recent advances in immuno-oncology and its application to urological cancers.Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.Upregulation of long noncoding RNA LOC440040 promotes tumor progression and predicts poor prognosis in patients with prostate cancer.A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.Gelsolin-like actin-capping protein is associated with patient prognosis, cellular apoptosis and proliferation in prostate cancer.The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
P2860
Q26740601-BFD77B93-15C4-47C2-99CB-87E33FF00320Q26864390-59E22AC7-0E8B-4E29-BA06-44007AC3CD33Q33589310-469CD9D5-6797-4267-8D58-F411525C4D0BQ34043994-6E3926EA-A532-4701-B678-27702004BAF8Q34748629-942BD504-D86F-4052-AA67-F3A152A1C154Q35110884-B99136F8-E5F6-4642-9432-E98FA85A827DQ35843039-6D78BF57-DC09-4794-ABAA-5B7EAD2C5C2FQ35845496-99827B09-F292-411C-A029-F6E5373883E8Q38362051-6E2093D0-37B1-4E1F-B1DF-6861CB052BEFQ38774648-C6A71111-8B06-4A60-B9C0-020B0696940BQ38819745-82884EDB-F41B-494E-B83F-51F098D0A708Q38972549-6EB0CAE4-4ECE-45FE-838A-F0E068E7293AQ39093352-F0A0E910-1936-4E87-87F6-0A8AA961076DQ41636538-768E65F1-F32F-4553-843A-0129891D0E69Q42687941-54EE614F-E492-4BCC-B6C5-F9BB41569744Q48505154-6135CE5F-7219-44CD-9B39-8B7ADC2293E2Q51281894-346F1508-9FD2-410D-9C8F-EF9B0DF46D14Q52874472-C5CEB700-C73E-410F-BA5F-7D438DCF48D3Q53809365-B757F735-F015-47D7-A55F-97215E908D61
P2860
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
@en
type
label
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
@en
prefLabel
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.
@en
P2093
P2860
P356
P1476
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens
@en
P2093
Berit A Snijer
Harm Westdorp
Pierre P Major
Ronan Foley
Sasja F Mulder
Sebastian Franik
Winald R Gerritsen
P2860
P356
10.3389/FIMMU.2014.00191
P577
2014-05-06T00:00:00Z